The WACC of Enlie Pharmaceutical JSC (BCP.VN) is 7.9%.
| Range | Selected | |
| Cost of equity | 6.20% - 8.80% | 7.50% |
| Tax rate | 1.40% - 2.60% | 2.00% |
| Cost of debt | 8.00% - 9.10% | 8.55% |
| WACC | 6.9% - 8.8% | 7.9% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.37 | 0.48 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.20% | 8.80% |
| Tax rate | 1.40% | 2.60% |
| Debt/Equity ratio | 0.68 | 0.68 |
| Cost of debt | 8.00% | 9.10% |
| After-tax WACC | 6.9% | 8.8% |
| Selected WACC | 7.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BCP.VN:
cost_of_equity (7.50%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.37) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.